Previous close | 12,026.00 |
Open | 12,070.00 |
Bid | 11,980.00 x 0 |
Ask | 11,984.00 x 0 |
Day's range | 11,882.00 - 12,144.00 |
52-week range | 9,461.00 - 12,186.00 |
Volume | |
Avg. volume | 2,944,566 |
Market cap | 185.842B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.00 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.28 (1.90%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M
CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).